{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-152247","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.125597+00:00","generated_at":"2026-06-25T12:18:56.352517+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inhibikase Therapeutics enters ATM equity distribution agreement for up to $9.8M through Piper Sandler","bullets":["Aggregate offering price up to $9,801,287 of common stock; sales at market prices via Piper Sandler.","Agent receives 3.0% commission on gross proceeds; expense reimbursement up to $75k upfront + $15k per quarter.","Sales made under existing shelf registration (Form S-3, File 333-262551) effective Feb 2022.","Company has no obligation to sell; may suspend or terminate the agreement at any time.","Customary representations, warranties, and indemnification provisions included."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-152247","json":"https://secwatch.observer/filing/0001193125-22-152247.json","markdown":"https://secwatch.observer/filing/0001193125-22-152247.md","text":"https://secwatch.observer/filing/0001193125-22-152247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522152247/0001193125-22-152247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522152247/d288031d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T12:18:56.352517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}